This acquisition expands Endpoint into clinical supply planning while keeping Bluefin independent and RTSM-agnostic.

此次收购将Endpoint的业务扩展至临床供应规划领域，同时保持Bluefin的独立性及其对随机化与试验供应管理（RTSM）系统的中立性。

RALEIGH, N.C. and BOSTON

北卡罗来纳州罗利和波士顿

,

，

Sept. 14, 2026

2026年9月14日

/PRNewswire/ -- Endpoint Clinical L.P., a global leader in randomization and trial supply management ('RTSM') solutions and a portfolio company of Arsenal Capital Partners, today announced it has acquired Bluefin, a Boston-based provider of clinical supply forecasting and planning technology.

/PRNewswire/ -- Endpoint Clinical L.P. 是全球随机化和试验供应管理（“RTSM”）解决方案的领导者，也是 Arsenal Capital Partners 旗下投资组合公司，今日宣布收购 Bluefin。Bluefin 是一家总部位于波士顿的临床供应预测和规划技术提供商。

The acquisition expands Endpoint into clinical supply chain planning while keeping Bluefin focused on its core forecasting and planning mission. Bluefin will operate independently and continue to connect with RTSM systems across the industry. Endpoint will support Bluefin with global project management, implementation, quality, and customer support capabilities to help sponsors deploy the platform reliably and efficiently..

此次收购使Endpoint的业务扩展至临床试验供应链规划领域，同时让Bluefin继续专注于其核心的预测与规划使命。Bluefin将独立运营，并继续与行业内的随机试验供应管理（RTSM）系统保持对接。Endpoint将为Bluefin提供全球项目管理、实施、质量及客户支持能力，协助申办方可靠且高效地部署该平台。

'Clinical supply planning is becoming more complex, more connected to trial execution, and more dependent on timely intelligence,' said Nagaraja 'Sri' Srivatsan, Chief Executive Officer of Endpoint Clinical. 'Bluefin gives Endpoint a strong foundation in clinical supply planning while preserving customer choice across RTSM providers.

“临床供应规划正变得日益复杂，与试验执行的关联更加紧密，并且更加依赖及时的情报支持。”Endpoint Clinical 首席执行官 Nagaraja “Sri” Srivatsan 表示。“Bluefin 为 Endpoint 在临床供应规划方面奠定了坚实的基础，同时保留了客户在不同 RTSM 供应商之间的选择权。”

Together, we have the opportunity to bring intelligence into every aspect of clinical supply, connecting planning, forecasting, enrollment signals, inventory movement, and RTSM execution data so every sponsor can make faster, better-informed decisions across all their studies. Endpoint can also bring the implementation discipline and support needed to deploy these capabilities reliably at scale.'.

我们携手合作，有机会将智能融入临床供应链的各个环节，打通规划、预测、入组信号、库存流动以及随机试验供应管理（RTSM）执行数据，使每一位申办方都能在其所有研究中做出更快速、更明智的决策。Endpoint 还能提供实施这些能力所需的方法论规范与支持，确保其可靠地大规模部署。

Clinical supply teams have long recognized that better outcomes come from connecting supply plans to the data that trials generate in real time; the challenge has been bringing those data sources together in a way that supports timely, actionable decision-making. Endpoint and Bluefin are helping close that gap, linking supply plans to trial execution data so teams can anticipate enrollment shifts and automate forecasting rather than react to them.

临床供应团队早已认识到，将供应计划与试验实时生成的数据相连接能够带来更好的结果；而挑战在于如何以支持及时、可操作决策的方式整合这些数据源。Endpoint 和 Bluefin 正在帮助弥合这一差距，将供应计划与试验执行数据相链接，使团队能够预判入组变化并实现预测自动化，而非被动应对。

Bluefin will maintain its open, RTSM- and forecasting-agnostic model, which both companies see as core to advancing the industry..

Bluefin 将保持其开放、与 RTSM 和预测无关的模型，两家公司都认为这是推动行业发展的核心。

'We're thrilled to be joining the Endpoint team,' said Andy Maltun, Co-Founder and Chief Executive Officer of Bluefin. 'The connection between RTSM and clinical supply forecasting is so natural that it's one of the first opportunities we discuss with every sponsor. Together, we are building a clinical supply intelligence platform that uses modern technology to automate manual work, reduce risk, and lower cost through optimized supply plans.'.

“我们非常高兴能够加入 Endpoint 团队，”Bluefin 联合创始人兼首席执行官 Andy Maltun 表示。“RTSM 与临床供应预测之间的关联如此自然，以至于它成为我们与每位申办方讨论的首要机会之一。我们将携手打造一个临床供应智能平台，利用现代技术自动化手工操作，通过优化的供应计划降低风险并降低成本。”

'This acquisition is consistent with our strategy of building technology-rich companies that solve meaningful enterprise problems for healthcare customers,' said Mark A. Goldberg, MD, Chairman of the Board of Directors of Endpoint Clinical and Operating Partner at Arsenal Capital Partners. 'Endpoint gains a path into clinical supply planning, Bluefin gains resources to scale, and the market continues to benefit from an independent planning platform that works across any RTSM environment.' Arsenal acquired Endpoint Clinical in 2024 and continues to support the company's growth and evolution of its RTSM platforms and AI capabilities..

“此次收购符合我们打造技术密集型企业的战略，旨在为医疗健康领域的客户解决具有实际意义的企业级难题，”Endpoint Clinical 董事会主席兼 Arsenal Capital Partners 运营合伙人 Mark A. Goldberg 医学博士表示。“Endpoint 由此切入临床供应规划领域，Bluefin 则获得扩大规模所需的资源，而市场将继续受益于一个能够在任何随机化与试验供应管理（RTSM）环境中运行的独立规划平台。”Arsenal 于 2024 年收购了 Endpoint Clinical，并持续支持该公司的增长及其 RTSM 平台和人工智能能力的演进。

By bringing clinical supply planning closer to real-time trial execution, Endpoint and Bluefin aim to give sponsors greater intelligence and confidence in managing increasingly complex global studies.

通过将临床供应计划与实时试验执行更紧密地结合，Endpoint 和 Bluefin 旨在为申办方提供更强的智能支持和信心，以管理日益复杂的全球性研究。

For more information, visit

更多信息，请访问

Endpoint Clinical

Endpoint Clinical

and

和

Bluefin

蓝鳍金枪鱼

.

。

About Endpoint Clinical

关于 Endpoint Clinical

Endpoint Clinical is a trusted clinical trial technology and service partner that delivers reliable RTSM solutions. Endpoint blends seamlessly into clinical trial processes by providing anticipatory and adaptive solutions to proactively mitigate risks. With decades of experience, Endpoint offers a deep understanding of the challenges that sponsors and CROs face.

Endpoint Clinical 是一家值得信赖的临床试验技术与服务合作伙伴，提供可靠的随机化与试验供应管理（RTSM）解决方案。Endpoint 通过提供前瞻性和自适应的解决方案，主动降低风险，从而无缝融入临床试验流程。凭借数十年的经验，Endpoint 对申办方和合同研究组织（CRO）所面临的挑战有着深刻的理解。

Its tech-forward dedication to innovation and high-touch services enable Endpoint to control the controllables and proactively generate speedy, strategic solutions, so sponsors and CROs can focus on running seamless clinical trials..

Endpoint 秉持以技术为驱动的创新理念和高触感服务模式，使其能够掌控可控因素，并主动提供快速、战略性的解决方案，从而让申办方和合同研究组织（CRO）能够专注于开展无缝衔接的临床试验。

About Bluefin

关于 Bluefin

Bluefin is a clinical supply forecasting and planning technology company focused on helping sponsors and CROs make smarter, data-driven supply decisions. Its platform enables organizations to forecast demand, evaluate supply scenarios, optimize distribution strategies, and proactively manage supply risk across the clinical trial lifecycle.

Bluefin 是一家专注于临床供应预测与规划的技术公司，致力于帮助申办方和合同研究组织（CRO）做出更智能、数据驱动的供应决策。其平台使组织能够在临床试验全生命周期中预测需求、评估供应情景、优化分销策略，并主动管理供应风险。

Through advanced modeling and planning capabilities, Bluefin helps clinical supply teams improve visibility, increase operational confidence, and support more efficient trial execution..

凭借先进的建模与规划能力，Bluefin 帮助临床供应团队提升可视化水平，增强运营信心，并支持更高效的临床试验执行。

About Arsenal Capital Partners

关于阿森纳资本合伙公司

Arsenal Capital Partners is a leading private equity investment firm that specializes in building market-leading industrial growth and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds totaling more than $10 billion, completed more than 300 platform and add-on acquisitions, and achieved more than 35 realizations.

Arsenal Capital Partners 是一家领先的私募股权投资公司，专注于打造市场领先的工业增长和医疗健康领域企业。自2000年成立以来，Arsenal 已募集超过100亿美元的机构股权投资基金，完成了300多项平台型及补充性收购，并实现了35多个项目的退出。

The firm partners with management teams to build strategically important companies with leading market positions, high growth, and high value-add. For more information, visit .

本公司与管理团队合作，打造具有领先市场地位、高增长和高附加值的战略重要企业。欲了解更多信息，请访问。

www.arsenalcapital.com

www.arsenalcapital.com

.

。

Media Contact

媒体联系人

Isabella Buhman

伊莎贝拉·布曼

[email protected]

[email protected]

SOURCE Endpoint Clinical

来源：Endpoint Clinical

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示